A new medication to be launched by the end of this year by US Pharma major Eli Lilly, to enhance its diabetes treatment portfolio in India.
A regulatory approval for the upcoming product has already been received by the company. It is also gearing up to introduce another medication in oncology that could be launched by the end of 2016 or early 2017 which has been filed for approvals.
"We are planning to introduce a new medication later this year in diabetes. We have received approvals for the same," told Edgard A Olaizola, Managing Director, Eli Lilly and Company India Pvt Ltd.
Diabetes is the primary segment for Eli Lilly in India with "around 60 to 70% of our revenues in India coming from diabetes followed by oncology and the osteoporosis," said Olaizola.
A range of medicines and drug delivery devices in the diabetes segment are sold by the company. It introduced an insulin delivery device called Savvio in India last year. Commenting on the significance of the Indian market for Eli Lilly, he added: "India is a very important market for the company in Asia." The US, Europe as a region and Japan are the biggest market for the company globally.
When asked about the Lilly NCD Partnership, Olaizola said, "The Lilly NCD Partnership is our response to the rising burden of non-communicable diseases (NCDs). It is a five year project in four countries -- India, Brazil, Mexico and South Africa with a commitment of USD 30 million over five years. Two pilot cities for NCD Partnership in India are Vizag and Sonipat", he added.